On July 23, 2020, Centus Biotherapeutics received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for EQUIDACENT, a biosimilar to AVASTIN (bevacizumab), intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.  Centus Biotherapeutics is a joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca.

Last month, we provided an update on a number of other bevacizumab biosimilar candidates.